These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22995541)

  • 1. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review.
    Kapp N; Gaffield ME
    Contraception; 2013 May; 87(5):576-82. PubMed ID: 22995541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When can a woman have repeat progestogen-only injectables--depot medroxyprogesterone acetate or norethisterone enantate?
    Paulen ME; Curtis KM
    Contraception; 2009 Oct; 80(4):391-408. PubMed ID: 19751863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective use of hormonal contraceptives: Part II: Combined hormonal injectables, progestogen-only injectables and contraceptive implants.
    Chrisman CE; Curtis KM; Mohllajee AP; Gaffield ME; Peterson HB
    Contraception; 2006 Feb; 73(2):125-33. PubMed ID: 16413843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When can a woman start combined hormonal contraceptives (CHCs)? A systematic review.
    Brahmi D; Curtis KM
    Contraception; 2013 May; 87(5):524-38. PubMed ID: 23153903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA.
    Nelson AL; Katz T
    Contraception; 2007 Feb; 75(2):84-7. PubMed ID: 17241834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
    Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable contraceptives.
    Toppozada M
    Contracept Deliv Syst; 1982 Apr; 3(2):161-70. PubMed ID: 12338171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
    Morroni C; Grams M; Tiezzi L; Westhoff C
    Contraception; 2004 Jul; 70(1):19-23. PubMed ID: 15208048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E(2)-cypionate: effects on ovarian function.
    Petta CA; Hays M; Brache V; Massai R; Hua Y; Alvarez-Sánchez F; Croxatto H; d'Arcangues C; Cook LA; Bahamondes L
    Fertil Steril; 2001 Apr; 75(4):744-8. PubMed ID: 11287029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Parenteral contraceptive drugs: depot progestins].
    Rabe T; Runnebaum B
    Wien Med Wochenschr; 1987 Nov; 137(20-21):474-9. PubMed ID: 2967589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection.
    Sneed R; Westhoff C; Morroni C; Tiezzi L
    Contraception; 2005 Feb; 71(2):99-103. PubMed ID: 15707558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review.
    Callahan R; Yacobson I; Halpern V; Nanda K
    Contraception; 2015 Dec; 92(6):514-22. PubMed ID: 26363431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestin-only injectables offer many advantages.
    Finger WR
    Netw Res Triangle Park N C; 1995 Jun; 15(4):16-20. PubMed ID: 12289828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.